jRCT2041220019进行中（未招募）不适用
A Phase 2, Multicenter, Randomized, Open-label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 180
- 主要终点
- Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- 干预性
- 分配方式
- 随机
- 干预模型
- parallel assignment
- 主要目的
- treatment purpose
- 盲法
- open(masking not used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- Sign and date the informed consent form (ICF) prior to the start of any study-specific qualification procedures.
- Participant must have at least one lesion, not previously irradiated, amenable to core biopsy.
- Male or female subjects aged >=18 years
- Histologically or cytologically documented ES-SCLC.
- At least one measurable lesion according to RECIST v1.1 as assessed by the investigator.
- Prior therapy with at least one platinum-based line as systemic therapy for extensive-stage disease with at least two cycles of therapy (except in the case of early objective PD) and beginning with protocol version 3.0, a minimum of two previous lines of systemic therapy.
- Documentation of radiological disease progression on or after most recent systemic therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
排除标准
- Prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
- Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
- Clinically active brain metastases, spinal cord compression or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
- Any of the following conditions within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
- Clinically significant corneal disease.
- Uncontrolled or significant cardiovascular disease.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.
- Chronic steroid treatment (maximum dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/COPD) or topical steroids (for mild skin conditions) or intra-articular steroid injections.
- History of malignancy other than SCLC within the 3 years prior to enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal (GI) tract tumors and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
- History of allogeneic bone marrow, stem cell, or solid organ transplant.
- Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute- Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0), Grade <=1 or baseline.
- History of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
- Has active or uncontrolled hepatitis B or C infection.
- Active, known, or suspected autoimmune disease.
- Any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses, psychiatric illness/social situations, substance abuse).
- Has received a live vaccine within 30 days prior to the first dose of study drug.
- Female who is pregnant or breast-feeding or intends to become pregnant during the study.
- Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant.
- Known human immunodeficiency virus (HIV) infection that is not well controlled.
结局指标
主要结局
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC
时间窗: Up to approximately 36 months
ORR was the defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR based on RECIST version 1.1. - **CR**: Disappearance of all target lesions - **PR**: At least a 30% decrease in the sum of diameters of target lesions
次要结局
未报告次要终点
研究者
标识符
- jRCT 编号
- jRCT2041220019
日期
- 首次提交
- (4年前)
- 最近更新
- (去年)
相似试验
招募中
1 期
同适应症Radiotherapy to All Residual Lesions After ChemoimmunotherapyExtensive-stage Small Cell Lung CancerNCT06479473Anhui Provincial Hospital150
已完成
2 期
同适应症A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerExtensive-stage Small Cell Lung CancerNCT04702880Bristol-Myers Squibb135
已完成
2 期
同适应症Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung CancerExtensive-stage Small Cell Lung CancerNCT02323737Chinese Academy of Medical Sciences62
已完成
1 期
同适应症SGI-110 Plus Durvalumab/Tremelimumab in SCLCExtensive-stage Small Cell Lung CancerNCT03085849Catherine Shu2
已完成
2 期
同适应症A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung CancerNCT04636762Second Xiangya Hospital of Central South University40